CAPPED BONUS-ZERTIFIKAT - GILEAD SCIENCES | Market Closed - Deutsche Boerse AG 01:26:48 2024-06-06 pm EDT | ||
| 74.49 EUR | -0.45% |
|
| Current month | +5.49% | ||
| 1 month | -0.01% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-06 | 74.49 | -0.45% |
| 24-06-05 | 74.83 | +1.75% |
| 24-06-04 | 73.54 | -1.95% |
| 24-06-03 | 75 | +6.22% |
| 24-05-31 | 70.61 | -4.41% |
Delayed Quote Deutsche Boerse AG
Last update June 06, 2024 at 01:26 pm EDT
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Citi
|
| WKN | KH4MC7 |
| ISIN | DE000KH4MC72 |
| Date issued | 2023-03-24 |
| Strike | 94 $ |
| Maturity | 2024-06-20 (14 Days) |
| Parity | 1 : 1 |
| Emission price | 69.98 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 83.93 € |
|---|---|
| Lowest since issue | 68.32 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
63.85
USD
Average target price
82.7
USD
Spread / Average Target
+29.52%
- Stock Market
- Certificates
- Certificat
